###### Key questions

What is already known about this subject?
=========================================

-   Cardiac changes and the significance of increased high-sensitivity troponin I (hs-TnI) have not been studied extensively in hypertensive disorders of pregnancy (HDP), although HDP is a risk factor for heart failure.

What does this study add?
=========================

-   Greater antepartum left atrial volume and inferior vena cava diameter, higher peripartum hs-TnI level, and lower early diastolic mitral annular velocity (e\') at 1 month postpartum were characteristic features of HDP.

-   Peripartum hs-TnI level was negatively correlated with later e\' at 1 month postpartum.

How might this impact on clinical practice?
===========================================

-   Peripartum hs-TnI rise is likely to occur in HDP and predicts poor left ventricular relaxation ability at 1 month postpartum.

Introduction {#s1}
============

Hypertensive disorders of pregnancy (HDP) are a risk factor for both peripartum cardiomyopathy (PPCM)[@R1] and cardiomyopathy in later life.[@R4] Indeed, the levels of cardiac biomarkers, such as brain natriuretic peptide (BNP) and troponin I, are increased in women with HDP compared with those with normotensive control pregnancy (NCP).[@R5] These observations suggest that somewhat pathological cardiac remodelling, that is, relative lack of capillary density and replacement with fibrosis,[@R8] is more likely to occur in HDP than in NCP.

Blood volume increases physiologically by approximately 40% in pregnancy,[@R10] and this volume expansion is associated with morphofunctional cardiac changes in pregnancy, such as increased left ventricular (LV) mass,[@R11] increased left atrial (LA) volume,[@R11] decreased systemic vascular resistance (SVR)[@R13] and significantly reduced ratio of early to late diastolic transmitral flow velocity.[@R11] As the maximal cardiac changes in morphology occur within 1 week after childbirth,[@R14] pathological remodelling may be likely to occur around childbirth. Troponin I reflects cardiac remodelling[@R8] and predicts the outcome of patients with heart failure.[@R8] PPCM is characterised by reduced LV ejection fraction (LVEF) and is accompanied by persistent LV diastolic dysfunction. If this is indeed the case, perinatal troponin I would predict a sustained decrease in LV relaxation monitored by early diastolic mitral annular velocity in pregnant women.

The degree of volume expansion is lower in HDP, especially in pregnancies complicated by preeclampsia,[@R16] while LV preloading monitored by LA volume is increased to a greater extent[@R11] in HDP compared with NCP. Preeclampsia is characterised by sympathetic overactivity[@R17] and a marked increase in SVR.[@R13] Splanchnic organs constitute 10% of the body weight, but contain 25% of the total blood volume, and thus the splanchnic vasculature serves as an important blood reservoir for the circulatory system.[@R18] Sympathetic activation expels blood from splanchnic capacitance vessels, producing a rapid increase in venous return up to 800 mL.[@R18] If this is the case in HDP, the inferior vena cava (IVC) diameter and LA volume would be increased in women with HDP, resulting in increased risk of heart failure compared with those with NCP.

This study was performed to better characterise the heart in HDP in relation to various cardiac biomarkers, using longitudinally prospectively collected data on simultaneous echocardiography and blood variables from women with HDP.

Methods {#s2}
=======

Participants {#s2-1}
------------

This project began in April 2014. All pregnant women who were scheduled to give birth at Hokkaido University Hospital were invited to participate in this study. All participants were recommended to undergo echocardiography at each of the first, second and third trimesters of pregnancy, and immediately postpartum within 1 week after childbirth (designated as 'PP1') and approximately 1 month postpartum (designated as 'PP2') on enrolment, and to provide blood samples at the same time as each echocardiography scan. Of 701 Japanese women with singleton pregnancies who gave birth at the Hokkaido University Hospital during the 2-year study period between April 2014 and March 2016, 151 women undergoing simultaneous echocardiography and blood sampling at least once participated in this project. Of these 151 women, 24 fulfilled both of the following criteria: (1) having these tests during at least three of five stages of pregnancy/postpartum; and (2) complication with HDP, including chronic hypertension, gestational hypertension and preeclampsia, in the current pregnancy. Hypertension was defined as systolic blood pressure ≥140 mm Hg and/or diastolic blood pressure ≥90 mm Hg on at least two occasions recorded 12 hours apart in pregnancy. Chronic hypertension was defined as hypertension noticed before gestational week 20 with no proteinuria. Gestational hypertension was defined as onset of hypertension at gestational week ≥20 with no proteinuria, and preeclampsia was defined as onset of both hypertension and proteinuria at gestational week≥20. The present study compared echocardiography findings and blood biomarkers of the 24 HDP with those of 51 NCP reported elsewhere.[@R14]

Echocardiographic evaluation, biochemical procedures and statistical methods {#s2-2}
----------------------------------------------------------------------------

Transthoracic echocardiography, including two-dimensional, colour Doppler and tissue Doppler imaging, was performed by a single trained operator (TU) blinded to the biochemical data using the same equipment (ProSound Alpha 7; Hitachi, Tokyo, Japan) according to the guidelines of the European Association of Cardiovascular Imaging.[@R20]

Biochemical procedures {#s2-3}
----------------------

Serum and plasma were collected at the time of each echocardiography scan and stored at --20°C until assays of the following four biomarkers: high-sensitivity troponin I (hs-TnI), N-terminal pro--B-type natriuretic peptide (NT-proBNP), BNP, and estimated glomerular filtration rate (eGFR) obtained using the following equation: 0.739×194×serum creatinine^--1.094^×age (years)^--0.287^.[@R21] The hs-TnI, BNP and NT-proBNP concentrations were measured using counting immunoassay kits (ARCHITECT High-Sensitivity Troponin-I, ARCHITECT BNP-JP and ARCHITECT CK-MB (Abbott Japan, Chiba, Japan) and Elecsys proBNP II STAT Assay (Roche Diagnostics KK, Tokyo, Japan), respectively).

Statistical methods {#s2-4}
-------------------

Statistical analyses were performed using JMP Pro V.12 (SAS, Cary, North Carolina, USA) and SPSS Statistics V.24.0. Changes in variables within a group were compared using Wilcoxon's rank-sum test and Student's t-test with Bonferroni correction. The associations between echocardiographic parameters and biomarker levels at five time points (first, second and third trimesters, and PP1 and PP2) were tested using the mixed effects model to examine the correlations at each time point. Dependent (echocardiographic parameters) and independent (biomarker levels) variables were standardised to interpret the regression coefficients as the correlation coefficients. The covariance structure at each time point showed compound symmetry. In all analyses, p\<0.05 was taken to indicate statistical significance. However, a significant finding regarding a linear correlation between two standardised variables was defined as that meeting both p\<0.05 and standardised regression coefficient (β)\>0.25 or \<--0.25. For analyses of the associations between peripartum biomarker levels with later e\' at 1 month postpartum (PP2), Pearson's product-moment correlation coefficient was used to measure linear correlations.

Results {#s3}
=======

Twenty-four women with HDP and 51 women with NCP underwent echocardiography 95 times (average, 4.0 times/person) and 255 times (5.0 times/person), respectively ([table 1](#T1){ref-type="table"}); 14 (58%) vs 51 (100%), 16 (67%) vs 51 (100%), 19 (79%) vs 51 (100%), 24 (100%) vs 51 (100%), and 22 (92%) vs 51 (100%) of the 24 women with HDP vs 51 women with NCP underwent simultaneous echocardiography and blood sampling at the first, second and third trimesters, and at PP1 and PP2, respectively. All data of women with NCP are reported elsewhere (online [supplemental table](#ST1){ref-type="supplementary-material"}).[@R14]
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###### 

Demographic characteristics of participants and timing of examination

                                 NCP                   HDP                  Pvalues
  ------------------------------ --------------------- -------------------- ---------
  Women (n)                      51                    24                   
  Nulliparouswomen               30(59%)               18(75%)              0.173
  Age(year)                      34.3±5.1              35.6±5.6             0.198
  Gestational week at delivery   38.9±1.3              35.1±4.9             \<0.001
  Weekly weight gain, kg\*       0.25±0.10             0.31±0.20            0.127
  Infant weight, kg              3.1±0.4               2.2±1.1              \<0.001
  Number of tests† given         255                   95                   
  Number of tests† per woman     5.0±0.0, 5 (5--5)     4.0±0.8, 4 (3--5)    \<0.001
  Timing of the tests†                                                      
  First trimester, weeks         11.6±1.2 (51, 100%)   11.3±0.9 (14, 58%)   
  Second trimester, weeks        25.2±1.0 (51, 100%)   25.2±1.2 (16, 67%)   
  Third trimester, weeks         36.4±0.6 (51, 100%)   35.6±2.6 (19, 79%)   
  PP1 (postpartum days 2--6)     3.3±0.8 (51, 100%)    3.4±1.1 (24, 100%)   
  PP2 (postpartum days 23--39)   30.9±3.7 (51, 100%)   30.2±3.3 (22, 92%)   

Data are presented as mean±SD. HDP, hypertensive disorders of pregnancy including 2, 6 and 16 women with chronic hypertension, gestational hypertension and preeclampsia, respectively. The number of women with the tests is indicated in brackets.

\*Value of gestational weight gain divided by gestational week at delivery.

†The tests consisted of simultaneous echocardiography and blood sampling.

NCP, normotensive control pregnancy.

Changes in echocardiographic parameters in women with HDP versus women with NCP {#s3-1}
-------------------------------------------------------------------------------

Compared with women with NCP, women with HDP showed increased LV mass index due to increased LV wall thickness; decreased averages of early diastolic septal and lateral mitral annular velocity (e\'), causing increases in the ratio of early diastolic mitral flow velocity to e\' (E/e\') and the ratio of systolic pulmonary venous flow velocity to anterograde diastolic pulmonary venous flow velocity (S/D); decreased index of long axis contractility, that is, decreased average of systolic septal and lateral mitral annular velocity (s\'), but no significant changes in the index of short axis contractility, that is, shortening fraction; increased IVC diameter and LA volume index concomitant with increased SVR in the third trimester; and persistent postpartum reduced cardiac function, such as e\', s\' and S/D ([table 2](#T2){ref-type="table"}, [figure 1](#F1){ref-type="fig"}).

![Representative echocardiographic findings: women with HDP versus women with NCP. †P\<0.05 between the two groups. Vertical bars indicate ±SE. bpm, beats per minute; e\', average of early diastolic septal and lateral mitral annular velocity; E/A, ratio of early to late diastolic transmitral flow velocity; E/e\', ratio of early diastolic mitral flow velocity to e\'; HDP, hypertensive disorders of pregnancy; IVC, inferior vena cava; LA, left atrial; LV, left ventricular; LVDd, LV end-diastolic dimension; NCP, normotensive control pregnancy; PP1, immediately postpartum within 1 week after childbirth; PP2, approximately 1 month postpartum; s\', average of systolic septal and lateral mitral annular velocity; S/D, ratio of systolic pulmonary venous flow velocity to anterograde diastolic pulmonary venous flow velocity; SVR, systemic vascular resistance.](openhrt-2018-000829f01){#F1}

###### 

Echocardiographic and blood parameters in 24 women with hypertensive disorders of pregnancy.

  ------------------------------------------------------------------------------------------------------------------------------------------
                                          First trimester\   Second trimester\   Third trimester\     PP1\                 PP2\
                                          (n=14)             (n=16)              (n=19)               (n=24)               (n=22)
  --------------------------------------- ------------------ ------------------- -------------------- -------------------- -----------------
  **Clinical data**                                                                                                        

  Gestational week and postpartum day     11.3(0.9)          25.2(1.3)           35.6(2.6)            3.4(1.1)             30(3.3)

  Heart rate, beats/min                   70(10)             80(10)              75 (9)†              84 (16)\*†           76 (11)†

  **Echocardiographic parameters**                                                                                         

  LVDd, mm                                45.0(3.8)          46.1(3.7)           47.3(3.9)            47.5(6.0)            46.0(4.0)

  Shortening fraction,%                   34.0(3.2)          34.6(4.8)           34.6(4.0)            34.3(4.1)            32.1(5.4)

  Interventricular septum thickness, mm   7.5(0.9)†          8.4 (1.3)†          9.4 (1.2)\*†         9.7 (1.6)\*†         9.1 (1.2)\*†

  LV posterior wall thickness, mm         6.9 (0.9)†         8.0 (1.5)\*†        8.4 (1.1)\*†         9.0 (1.2)\*†         8.1 (1.1)\*†

  LV mass, g                              100.3(25.2)        125.3 (41.2)†       141.6 (21.8)\*†      152.8 (29.6)\*†      131.7 (31.6)\*†

  LV mass/BSA, g/m^2^                     61.7(14.8)         71.8 (20.9)†        82.0 (11.7)\*†       89.5 (15.5)\*†       79.5 (16.2)\*†

  Maximum LA volume, mL                   35.2(9.4)          46.2 (10.3)\*†      53.3 (13.2)\*†       54.4 (13.6)\*†       42.0 (9.0)†

  Maximum LA volume/BSA, mL/m^2^          21.6(5.7)          26.5 (4.9)†         30.7 (6.9)\*†        31.8 (7.6)\*†        25.2 (5.0)†

  Inferior vena cava diameter, mm         12.3(5.3)          13.5(3.5)           13.1 (2.9)†          15.3(5.3)            14.0(4.6)

  Stroke volume, mL                       69.3(7.1)          68.6(7.5)           72.6 (9.3)†          77.4 (12.4)\*        63.2(9.9)

  Cardiac output, L/min                   4.9(1.0)           5.5(0.8)            5.3(1.0)             6.3 (1.1)\*†         4.7(0.8)

  Systemic vascular resistance,\          1459(360)          1252 (187)†         1488 (405)†          1229 (249)†          1644 (281)†
  dyn·s/cm^5^                                                                                                              

  Mitral inflow E/A                       1.56(0.31)         1.45(0.27)          1.26(0.35)           1.35(0.58)           1.15 (0.31)\*†

  Pulmonary vein inflow S/D               1.01(0.32)         1.24(0.27)          1.23(0.23)           1.33 (0.41)\*†       1.33 (0.36)\*†

  TDI mitral annulus                                                                                                       

  s\' ave, cm/s                           9.6(1.1)           10.2 (1.8)†         9.1 (1.5)†           9.3 (1.8)†           9.0 (1.7)†

  e\' ave, cm/s                           13.7 (2.7)†        12.7 (2.1)†         10.7 (2.3)\*†        11.7 (2.1)†          10.7 (2.1)\*†

  E/e\' ave                               6.1 (1.4)†         6.3 (1.7)†          7.4 (2.1)†           7.6 (1.9)†           6.4 (1.8)†

  **Blood data**                                                                                                           

  NT-proBNP, pg/mL                        42 (33--67)        30 (17--71)         70 (30--199)†        185 (99--487)\*†     47 (19--74)

  BNP, pg/mL                              11.6 (8.4--14.7)   12.7 (6.4--19.6)†   17.9 (12.5--91.2)†   45.6 (19.5--110)\*   8.1 (2.9--11.3)

  hs-TnI, pg/mL                           1.3 (0.3--2.1)     1.4 (0.6--4.7)      3.6 (1.1--6.6)\*†    6.9 (3.3--12.7)\*†   1.6 (1.1--3.0)†

  eGFR, mL/min/1.73m^2^                   108 (94--133)      107 (94--121)†      91 (79--100)\*†      85 (80--97)\*†       89 (76--99)\*
  ------------------------------------------------------------------------------------------------------------------------------------------

Clinical and echocardiographic data are presented as means (SD). Blood data are presented as medians (25th--75th).

\*P\<0.05 versus baseline value of the same group determined in the first trimester.

†P\<0.05 versus the value of normotensive control women ([online supplementary table](#ST1){ref-type="supplementary-material"}).[@R14] Numbers of women with available data on BNP was limited; 14, 15, 16, 21, and 19 women at the 1st, 2nd, 3rd trimesters of pregnancy and PP1 (postpartum day 2--7), and PP2 (postpartum day 23--39), respectively.

A, late diastolic mitral flow velocity; BNP, brain natriuretic peptide; BSA, body surface area; D, anterograde diastolic pulmonary venous flow velocity; E, early diastolic mitral flow velocity; e\' ave, average of early diastolic septal and lateral mitral annular velocity; eGFR, estimated glomerular filtration rate; hs-TnI, high-sensitivity troponin I; LA, left atrium; LV, left ventricle; LVDd, LV end-diastolic dimension; NT-proBNP, N-terminal pro--B-type natriuretic peptide; s\' ave, average of systolic septal and lateral mitral annular velocity; S, systolic pulmonary venous flow velocity; TDI, tissue Doppler imaging.

Changes in blood variables in women with HDP versus women with NCP {#s3-2}
------------------------------------------------------------------

Women with HDP were characterised by increased peripartum levels of BNP, NT-proBNP and hs-TnI, and decreased levels of eGFR, compared with women with NCP ([figure 2](#F2){ref-type="fig"}).

![Changes in blood biomarker levels during pregnancy/postpartum. †P\<0.05 between the two groups. Vertical bars indicate 25th--75th percentile values. Data on BNP were determined in a limited number of women (see footnote for [table 2](#T2){ref-type="table"}). BNP, brain natriuretic peptide; HDP, hypertensive disorders of pregnancy; eGFR, estimated glomerular filtration rate; hs-TnI, high-sensitivity troponin I; NCP, normotensive control pregnancy; NT-proBNP, N-terminal pro--B-type natriuretic peptide; PP1, immediately postpartum within 1 week after childbirth; PP2, approximately 1 month postpartum.](openhrt-2018-000829f02){#F2}

Associations of biomarkers with echocardiographic parameters determined simultaneously during pregnancy and postpartum {#s3-3}
----------------------------------------------------------------------------------------------------------------------

All four blood variables shown in [figure 2](#F2){ref-type="fig"} were analysed with regard to correlations of four measurements on echocardiography, that is, LV end-diastolic dimension, LA volume index, LV mass index, LVEF and e\', using all data obtained from 24 women with HDP and 51 women with NCP. NT-proBNP, BNP and hs-TnI were significantly positively correlated with LA volume index and LV mass index, while eGFR showed significant negative correlations with these levels ([figure 3](#F3){ref-type="fig"}). Only eGFR was significantly correlated with e\'. BNP was the best predictor of LA volume index, while hs-TnI was the best predictor of LV mass index. None of the blood variables were significantly correlated with LVEF.

![Standardised regression coefficients between blood variable levels and echocardiographic measurements. All data on biomarkers and five echocardiographic parameters determined simultaneously in 24 women with HDP and 51 women with NCP were used for this analysis. β, standardised regression coefficient. The regression line was drawn for β\>0.25 or \<--0.25. When hs-TnI level was below the limit of detection (0.1 pg/mL), we assumed that hs-TnI was present at a serum concentration of 0.1 pg/mL. BNP, brain natriuretic peptide; e\', average of early diastolic septal and lateral mitral annular velocity; eGFR, estimated glomerular filtration rate; HDP, hypertensive disorders of pregnancy; hs-TnI, high-sensitivity troponin I; LA, left atrial; LV, left ventricular; LVDd, LV end-diastolic dimension; LVEF, LV ejection fraction; NCP, normotensive control pregnancy; NT-proBNP, N-terminal pro--B-type natriuretic peptide.](openhrt-2018-000829f03){#F3}

Correlations of biomarker levels around childbirth with later e\' at 1 month postpartum. {#s3-4}
----------------------------------------------------------------------------------------

Reduced LV relaxation monitored by e\' was characteristic of HDP and persisted until 1 month postpartum (PP2) in women with HDP ([figure 1](#F1){ref-type="fig"}). The hs-TnI levels at the third trimester and immediately postpartum (at PP1) exhibited significant negative correlations with later e\' at 1 month postpartum (PP2) ([figure 4](#F4){ref-type="fig"}), although hs-TnI was not correlated with e\' determined simultaneously ([figure 3](#F3){ref-type="fig"}). The eGFR levels at the third trimester and immediately postpartum (at PP1) exhibited significant positive correlations with later e\' at 1 month postpartum (at PP2) ([figure 4](#F4){ref-type="fig"}). The correlation coefficient (r value) was greater for hs-TnI than for eGFR. Thus, hs-TnI around childbirth was the best predictor of later e\' at 1 month postpartum (at PP2). The areas under the curves (AUCs) of the receiver operating characteristic curves (ROCs) were 0.82 and 0.81 for hs-TnI determined at the third trimester and immediately postpartum (PP1), respectively, in the prediction of reduced LV relaxation at 1 month postpartum (e\'\<7.7 cm/s, fifth percentile value of 51 women with NCP at 1 month postpartum) ([figure 5](#F5){ref-type="fig"}). The corresponding AUCs of ROC were 0.63 and 0.74 for eGFR determined at the third trimester and immediately postpartum (PP1), respectively (data not shown).

![Associations of peripartum biomarker levels with e\' at 1 month postpartum (PP2). BNP, brain natriuretic peptide; e\', average of early diastolic septal and lateral mitral annular velocity; eGFR, estimated glomerular filtration rate; hs-TnI, high-sensitivity troponin I; NT-proBNP, N-terminal pro--B-type natriuretic peptide; PP1, immediately postpartum within 1 week after childbirth.](openhrt-2018-000829f04){#F4}

![Receiver operating characteristic curves of hs-TnI at third trimester and immediately postpartum in the prediction of reduced e\' (\< 7.7 cm/s) at 1 month postpartum. The e\' of 7.7 cm/s corresponded to the fifth percentile value of 51 women with normotensive control pregnancy at 1 month postpartum. AUC, area under the curve; e\', average of early diastolic septal and lateral mitral annular velocity; hs-TnI, high-sensitivity troponin I.](openhrt-2018-000829f05){#F5}

Discussion {#s4}
==========

This study demonstrated increased IVC diameter and LA volume index with increased SVR and reduced e\' during the third trimester and postpartum persistence of reduced cardiac function as determined by e\', s\' and S/D in women with HDP compared with women with NCP. In pregnant women, the hs-TnI level around childbirth was significantly negatively correlated with later LV diastolic function as determined by e\' at 1 month postpartum.

Splanchnic organs serve as an important blood reservoir for the circulatory system.[@R18] This blood reservoir decreases with sympathetic activation, resulting in a rapid increase in venous return up to 800 mL. Preeclampsia is characterised by sympathetic overactivity,[@R17] and ischaemia occurs in the splanchnic organs in severe forms of preeclampsia, such as the hemolysis, elevated liver enzymes and low platelet (HELLP) syndrome.[@R22] Women with preeclampsia accounted for 67% (16/24) of women with HDP in this study (see footnote for [table 1](#T1){ref-type="table"}). It was speculated that all three factors, that is, reduced splanchnic blood reservoir leading to increased venous return, increased SVR and reduced LV diastolic function, contributed to increased IVC diameter and LA volume index despite decreased circulating blood volume in women with HDP.

HDP is a prominent risk factor of PPCM.[@R1] LV diastolic dysfunction usually results from impaired LV relaxation and is consistently seen in patients with cardiomyopathy.[@R24] As dynamic changes in circulating volume are likely to occur peripartum, we used only e\', and not mitral inflow, LA volume or E/e\', as an index of LV diastolic function in this study, and demonstrated persistent postpartum reduced LV relaxation (monitored by e\') in women with HDP. It was reasonably speculated that women with persistent postpartum reduced e\' were at higher risk of PPCM or future cardiomyopathy compared with those without such findings. PPCM is rare, occurring in 1 in 300--4000 pregnant women.[@R1] Determination of blood biomarkers capable of predicting long-lasting reduced e\' at childbirth would contribute to identification of women requiring follow-up regarding cardiac status on echocardiography. Therefore, the present study was performed to identify such biomarkers, and we found that peripartum hs-TnI was significantly negatively correlated with e\' at 1 month postpartum. Thus, peripartum hs-TnI predicted poor LV relaxation at 1 month postpartum in this study and may be useful in the detection of women requiring follow-up of cardiac status.

Both BNP/NT-proBNP and hs-TnI exhibited peak values immediately postpartum in both women with HDP and with NCP, consistent with the results of previous studies.[@R5] BNP is bioactive and cardioprotective, improving LV diastolic function,[@R26] and may be secreted in response to atrioventricular stretching to alleviate cardiac load,[@R27] perhaps simply reflecting the changes in heart morphology in pregnancy. The level of hs-TnI also reflects cardiac changes in morphology at the time of blood sampling, similar to BNP/NT-proBNP ([figure 3](#F3){ref-type="fig"}). In addition, as hs-TnI reflects LV fibrosis and cardiac myocyte damage,[@R8] it was reasonable that higher hs-TnI around childbirth predicted sustained reduction of e\' in this study.

A significantly positive correlation was observed between eGFR and e\' in this study, consistent with findings in non-pregnant subjects.[@R30] This suggested that reduced eGFR was likely to accompany increased E/e\', an index of LV end-diastolic pressure, as shown in [figures 1 and 2](#F1 F2){ref-type="fig"}. Pulmonary congestion as a sign of heart failure may be likely to occur under such conditions with increased LV end-diastolic pressure. HDP is a prominent risk factor for heart failure in pregnancy,[@R2] and both pulmonary congestion and impaired renal function indeed occur more often in HDP than NCP.[@R31] Thus, reduced eGFR can be considered as a sign of impaired renal function and as a precursor of pulmonary congestion in pregnancy. In addition, persistent postpartum reduced eGFR may be a risk factor of heart failure in future life.

Study limitations {#s4-1}
-----------------

The low prevalence rate of HDP (approximately 5.0%), delayed referral of patients with HDP to our hospital and acute worsening of the patient's condition followed by emergent caesarean section resulted in missing data in some women with HDP in this study. Because LV diastolic dysfunction is usually the result of impaired LV relaxation,[@R24] we did not use the proposed diastolic function criteria of Nagueh *et al* [@R24] for difference in age of subjects and used only e\' as an index of LV diastolic function in this study. These factors may have distorted the results.

Conclusions {#s5}
===========

Persistent postpartum reduced LV relaxation is a characteristic feature of women with HDP. Reduced splanchnic blood reservoir in addition to reduced LV diastolic function as well as increased SVR may have contributed to the increased third trimester IVC diameter and LA volume, resulting in increased risk of heart failure despite decreased circulating blood volume in women with HDP. A rise in hs-TnI around childbirth was associated with poor LV relaxation ability at 1 month postpartum.
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